Terril Brothers Inc. Has $28.51 Million Stake in Bristol-Myers Squibb Company (BMY)
Terril Brothers Inc. lifted its position in Bristol-Myers Squibb Company (NYSE:BMY) by 4.0% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 511,634 shares of the biopharmaceutical company’s stock after buying an additional 19,605 shares during the period. Bristol-Myers Squibb makes up 10.1% of Terril Brothers Inc.’s holdings, making the stock its 2nd largest position. Terril Brothers Inc.’s holdings in Bristol-Myers Squibb were worth $28,508,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Welch Investments LLC raised its stake in shares of Bristol-Myers Squibb by 3.9% in the 1st quarter. Welch Investments LLC now owns 2,109 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 79 shares in the last quarter. Blue Chip Partners Inc. raised its stake in shares of Bristol-Myers Squibb by 0.8% in the 1st quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 17 shares in the last quarter. American National Bank raised its stake in shares of Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 225 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of Bristol-Myers Squibb by 29.6% in the 1st quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 504 shares in the last quarter. Finally, V Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb in the 2nd quarter worth $126,000. 68.88% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Terril Brothers Inc. Has $28.51 Million Stake in Bristol-Myers Squibb Company (BMY)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/10/05/terril-brothers-inc-has-28-51-million-stake-in-bristol-myers-squibb-company-bmy.html.
A number of analysts have recently commented on BMY shares. BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, June 27th. Jefferies Group LLC restated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, July 12th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 target price on the stock. in a report on Tuesday, July 25th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $63.00 target price on shares of Bristol-Myers Squibb in a report on Wednesday, August 9th. Finally, Piper Jaffray Companies set a $60.00 target price on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $61.84.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Theodore R. Samuels II acquired 6,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the purchase, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
Bristol-Myers Squibb Company (NYSE:BMY) opened at 64.74 on Thursday. The stock’s 50 day moving average price is $61.15 and its 200-day moving average price is $56.54. The stock has a market cap of $106.17 billion, a P/E ratio of 23.64 and a beta of 1.19. Bristol-Myers Squibb Company has a one year low of $46.01 and a one year high of $64.79.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.69 EPS. On average, analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.41%. The ex-dividend date of this dividend is Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is presently 56.73%.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).
Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.